clinical_trials
Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer
Confidence86·multiple reportsImportance88NP-EVT-20261104-3B2DBAF
(MedPage Today) -- Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to findings from the phase III...
Read the original at the primary source
Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer
11/4/2026, 4:25:17 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —